Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price for the next-generation Promarker(R)D test system, the predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that its majority owned subsidiary OxiDx Pty Ltd will today present groundbreaking performance data showing that Thoroughbred horses racing without oxidative stress were 76% more likely to place and 49% more likely to win.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, provided the Chair's Address and Company Presentation to be presented at the Company's Annual General Meeting.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) released a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the Bell Potter Healthcare Conference, a virtual event being held 18-20 November 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that its cash reserves have been further strengthened by the receipt of $2.2 million in research and development tax incentive for the 2024-25 financial year.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced it has been awarded a $500,000 grant from the Western Australian Government to accelerate the commercialisation of its world-first blood test for endometriosis, a condition affecting one in nine women globally.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) Managing Director Dr. Richard Lipscombe is interviewed about the most recent Quarterly Report and the pipeline of precision diagnostic tests in commercialisation phase.
